
    
      This randomized phase III non-small cell lung cancer clinical trial is studying the effect of
      Alimta (pemetrexed) plus vandetanib to see how well the combination works compared to Alimta
      (pemetrexed) alone in patients who have previously been treated for non-small cell lung
      cancer (NSCLC).
    
  